ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment

NCT00005645 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Fallopian Tube Cancer
Metastatic Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

Interventions

DRUG: ILX-295501

Sponsor

Genzyme, a Sanofi Company